Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Maridebart Cafraglutide · AMG-133

Peptide · Agonist of GLP-1 receptor (GLP1R) and GIP receptor (GIPR) · developed by AMGEN

Phase 3 Most advanced trial
AMGN Developer
1 Registered trials

What is Maridebart Cafraglutide?

Maridebart cafraglutide (MariTide) is a GLP-1/GIP receptor agonist peptide administered subcutaneously. It is studied in obesity and heart failure with preserved or mildly reduced ejection fraction.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AMG-133, MariTide
Drug type
Peptide
Targets
GLP-1 receptor (GLP1R), GIP receptor (GIPR)
Mechanism
Agonist of GLP-1 receptor (GLP1R) and GIP receptor (GIPR)
Therapy area
Cardiovascular, Metabolic
Developer
AMGEN (AMGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
Z24U3U73HN

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07037459 Phase 3 Heart Failure With Preserved Ejection Fraction Recruiting AMGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Heart Failure With Mildly Reduced Ejection FractionHeart Failure With Preserved Ejection FractionObesity

Other drugs acting on GLP1R / GIPR

Dulaglutide FDA approved Orforglipron FDA approved Semaglutide FDA approved Tirzepatide FDA approved Avexitide Phase 3 DehydraTECH-semaglutide Phase 1 LY3537021 Phase 2 VK2735 Investigational

More from AMGEN

Apremilast FDA approved Blinatumomab FDA approved Carfilzomib FDA approved Denosumab FDA approved Erenumab FDA approved Evolocumab FDA approved Pegloticase FDA approved Prednisone FDA approved Romiplostim FDA approved Romosozumab FDA approved Sotorasib FDA approved Tarlatamab FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AMGN page.

Follow AMGN, the company behind Maridebart Cafraglutide

See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.